FOXRED1

Across TCGA pan-cancer cohorts, FOXRED1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FOXRED1 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher FOXRED1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FOXRED1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

CHOL, LUSC, and UCEC are the cancer types where FOXRED1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →
LUSC	DFS	Median	All	0.139	0.707	.022	12	view →
UCEC	DFS	Median	All	1.000	0.622	.017	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BRCA	OS	Median	All	0.154	0.578	.046	4	view →
STAD	DFS	Median	II,III,IV	1.000	0.630	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FOXRED1–CHOL (DFS)

Open the CHOL breakdown →